Cancer genomic profiling can be challenging for patients with limited tissue sample, especially in cancer types such as lung cancer where small biopsy samples coupled with low tumor cellularity are the norm. By performing macrodissection and utilizing our expertise in handling FFPE samples, ACT Genomics is able to offer high success rate in FFPE and provide more comprehensive information on copy number variation (CNV) and mutations, with a small amount of specimens.
ACTOnco® + comprehensive genomic profiling, ACT Genomics’ flagship panel, covers tumor mutational burden (TMB), microsatellite instability (MSI) status and immune-related genes to provide a more accurate prediction of ICI responses.
For every report, ACT Genomics provides one-on-one report consultation for ordering physician. Our user-friendly reports offer clinically significant insights through logically-organized content and intuitive graphics.
Identify More Evidence-Based Treatment Options
ACT Genomics panels are designed to support physicians with evidence-based and actionable insights to answer clinical challenges in cancer management. Identifying the genetic alterations harbored in the patient’s tumor and understanding how they affect cancer-related cell signaling pathways to drive tumor growth are the keys to finding suitable treatment strategies for each patient.
Comprehensive Genomic Profiling
Real-Time Monitoring with Liquid Biopsy
ACTMonitor® + uses circulating tumor DNA (ctDNA) to provide an early detection of cancer recurrence and drug resistance. ctDNA consists of fragments of DNA released from necrotic or apoptotic tumor cells into the blood stream. ACTMonitor® + detects the occurrence of variants that would lead to drug sensitivity or resistance, allowing assessment of treatment responses before changes can be observed by protein markers and in radioimages.
Cancer Monitoring
Real-time monitoring through blood specimen
Detects drug resistance
Assesses treatment responses
Identify High Risk Groups for Hereditary Cancer
Approximately 5-10% of cancers are caused by germline mutations. In addition to the well-characterized BRCA1/2, mutations in many other genes also cause a higher lifetime risk of cancer, up to 10-90 times higher than for someone without a mutation.
ACTRisk™ is a genetic test that analyzes 67 genes strongly associated with common hereditary cancers. It provides important genetic information that helps physicians and genetic counselors to precisely evaluate cancer risk and discuss risk management options with clients.
Hereditary Risk Evaluation
Analyzes 67 genes
Evaluates risk for 9 hereditary cancers and 11 cancer sydrome
Clinical trial results of tazemetostat for INI1/SMARCB1-negative epithelioid sarcoma 2020-12-22
In a phase II trial, the EZH2 inhibitor tazemetostat shown anti-tumor activity in epithelioid sarcoma with loss of INI1 protein expression or biallelic SMARCB1 gene mutation.
Novel Resistance Mechanism for Savolitinib in MET-Amplified Gastric Cancer 2020-12-22
In a gastric cancer-specific umbrella trial, the VIKTORY trial, scientists found that MET D1228V/N/H and Y1230C mutations or high copy number MET gene amplification might be the resistance mechanisms for savolitinib.
SUMMIT study provided another treatment options for NSCLC EGFR exon 18 mutations patients 2020-12-22
Pan-ErbB inhibitor neratinib showed a 40% objective response rate in pre-treated EGFR exon 18 NSCLC patients and a manageable safety profile according to interim results of SUMMIT study.
A new oral SERD drug, SAR439859, shown the anti-tumor activity in ER+/Her2- breast cancer 2020-11-20
SAR439859 is a new oral SERD drug. A phase I/II study shown the anti-tumor activity of SAR439859 in ER+/Her2- breast cancer patients previously treated with hormone therapy.
Adagrasib (MRTX849) showed efficacy and safety in KRASG12C NSCLCs from KRYSTAL-1 study 2020-11-20
Adagrasib was a well tolerated drug and demonstrated 45% objective responds and 96% of disease control rate in the heavily pre-treated KRASG12C mutant NSCLC patients.
CH5126766 is a novel potential treatment for RAS/RAF mutant cancers 2020-11-20
A small molecular inhibitor of RAF-MEK, CH5126766, showed its potential for treating RAS/RAF-mutant solid tumors in a phase 1 study.
Step 1.
We are highly experienced and possess professional high standard procedures in the challenging process of retrieving DNA from FFPE samples for sequencing. Our scientists have optimized the methodology to consistently achieve successful sequencing with highly accurate results. In addition to FFPE samples, our platform also works with core needle biopsies, pleural effusion, ascites, blood samples, and buccal swaps.
Step 2.
ACT Genomics has established a state-of-the-art next generation sequencing (NGS) platform. Sequencing is performed on Ion Personal Genome Machines, Ion Proton sequencers and Illumina MiSeq; ACT Genomics is an Ion Torrent™ Certified Service Provider.
Step 3.
ACT Genomics integrates advanced annotation and visualization tools, coupled with public and proprietary databases to deliver comprehensive and comprehensible reports.
Step 4.
With accurate genomic profiling, visualizing genes with alterations in known cancer pathways and providing potential matching cancer targeted treatments from FDA and National Comprehensive Cancer Network (NCCN) guidelines, mutated sub-network in known pathways, as well as references, ACT Genomics aims to deliver a concise, reliable and actionable meaningful clinical report.
